Why the study?
Do oral glucose-lowering agents affect the risk of life-threatening arrhythmias in patients with type 2 diabetes mellitus?
Do oral glucose-lowering agents affect the risk of life-threatening arrhythmias in patients with type 2 diabetes mellitus?
Different classes of oral glucose-lowering agents have heterogeneous effects on life-threatening arrhythmias in type 2 diabetes, with SGLT2 inhibitors showing potential benefits for atrial fibrillation and sudden cardiac arrest.
May support SGLT2 inhibitor use to lower AF/SCA risk in T2DM; leaves open ventricular arrhythmia effects pending prospective trials.
: The results concerning the impact of various GLA on VA/SCA were heterogeneous depending on the pharmacological class studied, with some of them having neutral, positive, or negative effects. Although it appears that SGLT2i reduces the prevalence of atrial fibrillation and SCA, their effect on VA is not conclusive.
No takes yet. Share an insight, caveat, or question.
Tudoran et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: